Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2016 8
2017 20
2018 23
2019 20
2020 23
2021 22
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Results by year
Filters applied: . Clear all The asterisk in your search was ignored. You must use 4 or more characters for a wildcard search. Lengthen the root word to search for all endings. The following term was ignored: ( Quoted phrase not found: "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6,11,16,18"
Page 1
Human papillomavirus and cervical cancer.
Okunade KS. Okunade KS. J Obstet Gynaecol. 2020 Jul;40(5):602-608. doi: 10.1080/01443615.2019.1634030. Epub 2019 Sep 10. J Obstet Gynaecol. 2020. PMID: 31500479 Free PMC article. Review.
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) infection. ...There are currently two effective prophylactic vaccines again …
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital …
Non-sexual HPV transmission and role of vaccination for a better future (Review).
Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Petca A, et al. Exp Ther Med. 2020 Dec;20(6):186. doi: 10.3892/etm.2020.9316. Epub 2020 Oct 13. Exp Ther Med. 2020. PMID: 33101476 Free PMC article. Review.
Waterborne transmission of HPV has never been demonstrated; however, HPV DNA has been detected in water environments. ...Once the HPV vaccine program in Australia was launched, many studies reported the initial effects: A decrease in the inciden …
Waterborne transmission of HPV has never been demonstrated; however, HPV DNA has been detected in water environments. ...Once …
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A. Huh WK, et al. Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5. Lancet. 2017. PMID: 28886907 Clinical Trial.
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and …
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHP …
Fanconi Anemia.
Mehta PA, Ebens C. Mehta PA, et al. 2002 Feb 14 [updated 2021 Jun 3]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. 2002 Feb 14 [updated 2021 Jun 3]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. PMID: 20301575 Free Books & Documents. Review.
Prevention of primary manifestations: Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in females, and possibly reduce the risk of oral cancer in all individuals. ...Evaluation of relatives at risk: DEB/MMC testing or molecula …
Prevention of primary manifestations: Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in fem …
Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case-control study.
Ikeda S, Ueda Y, Hara M, Yagi A, Kitamura T, Kitamura Y, Konishi H, Kakizoe T, Sekine M, Enomoto T, Sobue T. Ikeda S, et al. Cancer Sci. 2021 Feb;112(2):839-846. doi: 10.1111/cas.14682. Epub 2020 Dec 11. Cancer Sci. 2021. PMID: 33040433 Free PMC article.
Cervical cancer remains among the most common cancers in women worldwide and can be prevented by vaccination. The Ministry of Health, Labour and Welfare of Japan suspended active recommendation of regular human papillomavirus (HPV) vaccines in 2 …
Cervical cancer remains among the most common cancers in women worldwide and can be prevented by vaccination. The Ministry of Heal
Association Between Human Papillomavirus Vaccination School-Entry Requirements and Vaccination Initiation.
Ko JS, Goldbeck CS, Baughan EB, Klausner JD. Ko JS, et al. JAMA Pediatr. 2020 Sep 1;174(9):861-867. doi: 10.1001/jamapediatrics.2020.1852. JAMA Pediatr. 2020. PMID: 32597928 Free PMC article.
IMPORTANCE: Human papillomavirus (HPV) vaccination coverage is suboptimal in the US. The association between HPV vaccination requirements for school entry and HPV vaccination coverage remains to be studied. ...This study was conduc …
IMPORTANCE: Human papillomavirus (HPV) vaccination coverage is suboptimal in the US. The association between HPV
Human papillomavirus in Ethiopia.
Derbie A, Mekonnen D, Yismaw G, Biadglegne F, Van Ostade X, Abebe T. Derbie A, et al. Virusdisease. 2019 Jun;30(2):171-179. doi: 10.1007/s13337-019-00527-4. Epub 2019 Apr 20. Virusdisease. 2019. PMID: 31179353 Free PMC article. Review.
The top five identified genotypes were HPV 16 (45.3%; 95% CI 41.1-49.6%), HPV 52 (9.4%; 95% CI 7.2-12.1%), HPV 18 (8.2%; 95% CI 6.2-10.9%), HPV 58 (6.9%; 95% CI 5.1-9.4%) and HPV 45 (5.2%; 95% CI 3.7-7.5%). The combined prevalence of HPV
The top five identified genotypes were HPV 16 (45.3%; 95% CI 41.1-49.6%), HPV 52 (9.4%; 95% CI 7.2-12.1%), HPV 18 (8.2% …
Human papillomavirus vaccination: the population impact.
Lee LY, Garland SM. Lee LY, et al. F1000Res. 2017 Jun 12;6:866. doi: 10.12688/f1000research.10691.1. eCollection 2017. F1000Res. 2017. PMID: 28663791 Free PMC article. Review.
We currently have the knowledge and experience to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic HPV vaccination programs have been adopted as highly effective public he
We currently have the knowledge and experience to prevent much of human papillomavirus (HPV)-related disease burden globally. …
Human papillomavirus and cervical cancer.
Okunade KS. Okunade KS. J Obstet Gynaecol. 2019 Dec 11:1-7. doi: 10.1080/01443615.2019.1674261. Online ahead of print. J Obstet Gynaecol. 2019. PMID: 31825273
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) infection. ...There are currently two effective prophylactic vaccines again …
Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital …
Physicians' rhetorical strategies for motivating HPV vaccination.
Gilkey MB, Grabert BK, Malo TL, Hall ME, Brewer NT. Gilkey MB, et al. Soc Sci Med. 2020 Dec;266:113441. doi: 10.1016/j.socscimed.2020.113441. Epub 2020 Oct 13. Soc Sci Med. 2020. PMID: 33069959 Free PMC article.
OBJECTIVE: To qualitatively describe strategies providers use to motivate HPV vaccination. METHOD: We surveyed a national sample of 771 U.S. primary care physicians. ...Across these two sets of strategies, a tension emerged between the goals of engaging paren …
OBJECTIVE: To qualitatively describe strategies providers use to motivate HPV vaccination. METHOD: We surveyed a national samp …
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page